- IN₹16.84bn
- IN₹17.68bn
- IN₹6.15bn
- 64
- 26
- 88
- 67
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.43 | ||
Price to Tang. Book | 3.59 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2.64 | ||
EV to EBITDA | 20.49 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 13.87% | ||
Return on Equity | 12.74% | ||
Operating Margin | 11.42% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 3,594.99 | 4,918.14 | 4,775.21 | 5,509.87 | 6,145.92 | n/a | n/a | 11.42% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -10.64 | +186.88 | -3.44 | -58.99 | +87.11 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Kopran Limited is an India-based integrated pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (APIs). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include anti-infective, amoxycillin, ampicillin, cloxacillin and amoxy clauv. Its non-penicillin-based finished oral dosage forms include macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management and gastroenterology. It provides ingredients in a wide range of pharmaceutical products, such as capsules, injectables and tablets, among others. The Company's APIs products include anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems and sterile cephalosporins.
Directors
- Surendra Somani VCH (57)
- Ajit Jain COO (50)
- Sunil Sodhani CCO
- Susheel Somani DRC
- Adarsh Somani NED (44)
- Varun Somani NED (35)
- Sunita Banerji IND
- V. Bhandari IND
- Siddhan Subramanian IND
- A. Mehta NID
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- April 26th, 1958
- Public Since
- November 17th, 1992
- No. of Shareholders
- 51,705
- No. of Employees
- 358
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 48,210,605
- Address
- Parijat House, MUMBAI, 400018
- Web
- https://www.kopran.com/
- Phone
- +91 2243661111
- Contact
- Chandni Shah
- Auditors
- Khandelwal Jain & Co.
Upcoming Events for KOPRAN
Q3 2025 Kopran Ltd Earnings Release
Similar to KOPRAN
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 22:07 UTC, shares in Kopran are trading at IN₹349.35. This share price information is delayed by 15 minutes.
Shares in Kopran last closed at IN₹349.35 and the price had moved by +52.16% over the past 365 days. In terms of relative price strength the Kopran share price has outperformed the S&P BSE 100 Index by +16.55% over the past year.
The overall consensus recommendation for Kopran is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Kopran dividend yield is 0.86% based on the trailing twelve month period.
Last year, Kopran paid a total dividend of IN₹3.00, and it currently has a trailing dividend yield of 0.86%.Looking ahead, the next dividend pay date is 2024-10-11.
We do not have data on when Kopran is to next pay dividends. The historic dividend yield on Kopran shares is currently 0.86%.
To buy shares in Kopran you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹349.35, shares in Kopran had a market capitalisation of IN₹16.84bn.
Here are the trading details for Kopran:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: KOPRAN
Based on an overall assessment of its quality, value and momentum Kopran is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kopran. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +13.39%.
As of the last closing price of IN₹349.35, shares in Kopran were trading +33.2% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kopran PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹349.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kopran's management team is headed by:
- Surendra Somani - VCH
- Ajit Jain - COO
- Sunil Sodhani - CCO
- Susheel Somani - DRC
- Adarsh Somani - NED
- Varun Somani - NED
- Sunita Banerji - IND
- V. Bhandari - IND
- Siddhan Subramanian - IND
- A. Mehta - NID